LGND

Ligand Pharmaceuticals Incorporated Press Releases

$107.78
*  
0.92
0.86%
Get LGND Alerts
*Delayed - data as of Jul. 30, 2015  -  Find a broker to begin trading LGND now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844
7/30/2015 9:00:00 AM - Business Wire
▲0.86 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
7/24/2015 9:00:00 AM - Business Wire
▲3.63 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand to Report Second Quarter Results on August 4th
7/16/2015 5:30:00 PM - Business Wire
▲2.34 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand to Participate in Four Upcoming Investor Conferences
6/17/2015 5:00:00 PM - Business Wire
▲18.12 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
6/12/2015 8:00:00 AM - Business Wire
▲14.46 % Price Change since this news event. The Volume Ratio is 1.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial
6/7/2015 5:30:00 PM - Business Wire
▲14.57 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions
6/5/2015 4:30:00 PM - Business Wire
▲14.57 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance
6/2/2015 4:30:00 PM - Business Wire
▲27.29 % Price Change since this news event. The Volume Ratio is 1.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Reports First Quarter 2015 Financial Results
5/11/2015 8:30:00 AM - Business Wire